Benzinga · Sep 9, 2026
BTIG Reiterates Buy on Neuronetics, Maintains $6 Price Target
BTIG analyst Sam Eiber reiterates Neuronetics (NASDAQ:STIM) with a Buy and maintains $6 price target.
ST
NASDAQ · STIM
Neuronetics, Inc.
Healthcare · Medical - Diagnostics & Research
$3.04
Down-$0.03 (-0.99%)
Updated Sep 11, 2026, 1:33 AM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 94.17M
- P/E ratio
- -2.1
- Dividend yield
- 0.00%
- 52-week range
- $0.80 – $3.44
- Volume
- 1.42M
- Avg. volume
- 1.57M
Price performance
STIM price history
1M range · 19 trading sessions · Daily adjusted prices
STIM closed at $3.04 after 19 trading sessions, up 0.33% for the selected period.
- Last close
- $3.04
- Period change
- +0.33%
- Period low
- $2.72
- Period high
- $3.30
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $2.91 | $3.115 | $2.85 | $3.04 | 1.42M |
| Sep 8, 2026 | $2.85 | $3.01 | $2.82 | $2.93 | 1.43M |
| Sep 4, 2026 | $2.72 | $2.965 | $2.6804 | $2.88 | 996.61K |
| Sep 3, 2026 | $2.79 | $2.81 | $2.67 | $2.72 | 773.86K |
| Sep 2, 2026 | $2.85 | $2.89 | $2.70 | $2.77 | 1.08M |
| Sep 1, 2026 | $2.80 | $2.925 | $2.75 | $2.84 | 780.87K |
| Aug 31, 2026 | $2.95 | $2.96 | $2.76 | $2.84 | 964.22K |
| Aug 28, 2026 | $2.96 | $3.025 | $2.8809 | $2.94 | 865.14K |
| Aug 27, 2026 | $3.00 | $3.04 | $2.93 | $2.96 | 697.56K |
| Aug 26, 2026 | $2.905 | $3.015 | $2.88 | $3.00 | 640.5K |
| Aug 25, 2026 | $2.90 | $2.99 | $2.84 | $2.98 | 856.27K |
| Aug 24, 2026 | $2.98 | $3.00 | $2.8301 | $2.89 | 809.31K |
| Aug 21, 2026 | $3.11 | $3.15 | $2.99 | $3.00 | 1.03M |
| Aug 20, 2026 | $3.13 | $3.17 | $3.04 | $3.09 | 826.86K |
| Aug 19, 2026 | $3.16 | $3.26 | $3.025 | $3.14 | 1.31M |
| Aug 18, 2026 | $3.22 | $3.335 | $3.09 | $3.15 | 1.47M |
| Aug 17, 2026 | $3.272 | $3.40 | $3.06 | $3.27 | 1.87M |
| Aug 14, 2026 | $3.06 | $3.305 | $2.95 | $3.30 | 2.13M |
| Aug 13, 2026 | $3.17 | $3.43 | $3.00 | $3.03 | 4.17M |
Latest STIM news
The latest Smart Investors Daily articles mentioning STIM.
Stock researchCompany · Overview
STIM research
Overview
Company profile and research snapshot.
Company profile
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $8.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | BTIG | Buy | — |
| Aug 11, 2026 | BTIG | Buy | — |
| Jul 20, 2026 | BTIG | Buy | — |
| Mar 19, 2026 | Canaccord Genuity | Buy | — |
| Aug 6, 2025 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 8, 2026
NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System
First-of-Its-Kind Integration Connects TrakStar and AdvancedMD, Delivering TMS Care Across Clinical, Operational, and Billing WorkflowsMALVERN, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the integration of its TrakStar® practice management platform with AdvancedMD, a leading c
Benzinga · Aug 11, 2026
BTIG Maintains Buy on Neuronetics, Raises Price Target to $6
BTIG analyst Sam Eiber maintains Neuronetics (NASDAQ:STIM) with a Buy and raises the price target from $5 to $6.
SeekingAlpha · Aug 11, 2026
Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript
Neuronetics, Inc. (STIM) Q2 2026 Earnings Call August 11, 2026 8:30 AM EDTCompany ParticipantsDaniel Reuvers - CEO, President & DirectorNir Naor -...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
